Vitarka Therapeutics is a pre-clinical stage Biotech focused on the development of RNAi therapies and non-viral delivery platform technology.
Our combination therapeutics aim to activate the immune system and normalise the tumour vasculature, using state-of-the-art proprietary technologies.
Vitarka Therapeutics aims to combine state-of-the-art patented RNAi technology with non-viral delivery platform for two validated, druggable targets as 1st line for currently untreated patient populations and 2nd line for PD-1 resistant tumours.
First-in-class monotherapy would successfully address this major, unmet medical need. Combination of activating the immune system and vascular normalization for multi-modal efficacy would be a true game-changer for late-stage patients with lung, colon, breast, and other cancers.
Naturally occuring non-viral delivery with known mechanism-of-action leads to high precisoin with different therapies
SAFE AND FLEXIBLE
Difference receptor-binding specifities makes our non-viral delivery compatible with different cell types. Biocompatible to avoid unwanted responses and toxic effects.
IP PROTECTED AND CLINICALLY VALIDATED
Patent-protected (granted patents); tested in cell and animal-based assays as well as human clinical trials proof-of-concept
Applicable to various cell types, carrying different payloads with ease of manufacturing and deployment; Can be scaled to other targets and indications
Experienced leadership team with proven excellence in big pharma drug development including project management, study design, lead identification, optimization and clinical development.
Strong strategic network alliance of collaborators, experts, partners, associates and counsellors.